Chloroquine phosphate indications and usage: Difference between revisions
Created page with "__NOTOC__ {{Chloroquine phosphate}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CHLOROQUINE (CHLOROQUINE PHOSPHAT..." |
|||
(One intermediate revision by the same user not shown) | |||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications And Usage== | |||
Chloroquine Phosphate Tablets are indicated for suppressive treatment and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. The drug is also indicated for the treatment of [[extraintestinal amebiasis]]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET, COATED [WEST-WARD PHARMACEUTICAL CORP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b585ad5-ae86-4403-b83f-8d8363d43da5 | publisher = | date = | accessdate = }}</ref> | Chloroquine Phosphate Tablets do not prevent relapses in patients with [[vivax]] or [[malariae]] malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. It is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of P. falciparum.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET, COATED [WEST-WARD PHARMACEUTICAL CORP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b585ad5-ae86-4403-b83f-8d8363d43da5 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== |
Latest revision as of 18:37, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
Chloroquine Phosphate Tablets are indicated for suppressive treatment and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. The drug is also indicated for the treatment of extraintestinal amebiasis.
Chloroquine Phosphate Tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. It is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of P. falciparum.[1]
References
Adapted from the FDA Package Insert.